CVS Health announces midlife research and CVS Health stock costs EUR 82.49

Published on 10/16/2026 at 09:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Leerink cut its target from USD 119.00 to USD 112.00. CVS Health stock costs EUR 82.49 on October 16, 2026, 0.94 percent above the Xetra close.

Company events and operating scale

On October 15, 2026, CVS Health announced a research collaboration with The Midlife Collective.
Second-quarter 2026 revenue reached USD 106.10 billion, up 7.30 percent year over year.
CVS Health stock trades at EUR 82.49 at 9:15 a.m. CEST at Lang & Schwarz on October 16, 2026, 0.94 percent above the Xetra close of October 15, 2026.
CVS Health serves approximately 87 million pharmacy benefit manager members as of June 30, 2026.

Moderner Apothekenverkaufsraum mit Apothekerin und Kundin vor Medikamentenregalen — CVS Health Corp. zeigt fotorealen Apothekenverkaufsraum mit Apothekerin und Kundin, ISIN US1266501006, Illustration mit AI erstellt.

CVS Health (ISIN US1266501006) stock was trading at EUR 82.49 at Lang & Schwarz on October 16, 2026 at 9:15 a.m. CEST, plus 0.94 percent versus the Xetra close of October 15, 2026 (EUR 81.72). On October 15, 2026, CVS Health announced a research collaboration with The Midlife Collective, according to CVS Health.

Research adds a consumer-health angle

The project will study the physical, emotional and social experiences of women in midlife and inform a documentary called Her Second Act. CVS Health said the collaboration fits its wider health-services strategy, which combines pharmacy, insurance and care offerings.

The company said on October 15 that it operates approximately 9,000 retail pharmacy locations and more than 1,000 walk-in and primary care clinics as of June 30, 2026. Its pharmacy benefit manager serves approximately 87 million plan members, while its health insurance products reach an estimated 37 million people, according to CVS Health.

What does the latest quarter add?

Second-quarter 2026 revenue reached USD 106.10 billion, up 7.30 percent from the prior-year quarter. Diluted earnings per share rose to USD 2.58 from USD 1.81, while net income reached USD 2.98 billion, according to MarketBeat. The same report said adjusted earnings per share of USD 2.58 exceeded the USD 1.87 consensus estimate by USD 0.71.

Three dated company steps

On September 30, 2026, CVS Health approved a quarterly dividend of USD 0.665 per share, payable November 2, 2026, according to CVS Health. On October 5, 2026, the company scheduled its third-quarter results call for November 4, 2026, at 8:00 a.m. ET. On October 15, 2026, it announced the midlife research collaboration.

Dates investors can calculate

October 22, 2026 is the dividend record date, and November 4, 2026 is the scheduled third-quarter earnings date, according to CVS Health. The upcoming report will test whether the second-quarter revenue growth and higher earnings can continue into the second half.

Stock stays below its yearly high

CVS Health has a market capitalization of USD 118.4 billion as of October 15, 2026. Its primary-exchange 52-week range was USD 69.51 to USD 110.68, leaving the latest USD 92.58 NYSE quote below the high and above the low. The euro quotation remains the relevant reference for German investors in this article.

CVS Health was trading at EUR 82.49 at Lang & Schwarz on October 16, 2026 at 9:15 a.m. CEST, plus 0.94 percent versus the Xetra close of October 15, 2026 (EUR 81.72). The further course of trading is shown by the continuously updated real-time quote of CVS Health stock.